FDA seeks comment on device tracking and raises the burden estimate by 47,526 hours

MedDevice Startups Staff · 3 days ago · 2 min read · Via Federal Register

FDA opened comment on its medical device tracking information collection on September 11, under docket FDA-2026-N-9350. The notice covers the requirements in 21 CFR Part 821. Comments close November 10, 2026.

The agency now estimates 662,906 annual hours across about 22,000 manufacturers, importers and distributors. That is 47,526 hours above the previous estimate. FDA attributes the increase to more submissions in recent years.

Part 821 lets FDA order tracking for a Class II or Class III device whose failure would likely cause serious adverse health consequences. It also reaches devices implanted for more than a year and life sustaining devices used outside a care facility. The point of the rule is reaching the patient during a recall.

If your implant or home life sustaining device could draw a tracking order, the cost sits in your distributor agreements. Write the data and reporting obligations into those contracts before you sign. Retrofitting tracking duties onto a distribution network you already built is the expensive version.

Questions & Answers

What is the FDA medical device tracking notice published in September 2026?

FDA published a Paperwork Reduction Act notice on September 11, 2026 under docket FDA-2026-N-9350, asking for comment on the medical device tracking requirements in 21 CFR Part 821. Comments are due November 10, 2026.

Which devices can FDA require to be tracked under 21 CFR Part 821?

FDA can order tracking for Class II or Class III devices whose failure would likely cause serious adverse health consequences, devices implanted in a patient for more than one year, and life sustaining devices used outside a health care facility.

← Back to Regulatory